Experiment 67093
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | RUSSELL,AL: MC CARTY,MF:. (2000). GLUCOSAMINE FOR MIGRAINE PROPHYLAXIS?. 55(3) |
| Amount utilized | |
| Compound isolated | |
| Disease | FOLLOWING A FORTUITOUS OBSERVATION THAT MIGRAINE HEADACHES CEASED IN A PATIENT RECEIVING GLUCOSAMINE THERAPY FOR OSTEOARTHRITIS, A FURTHER TEN PATIENTS WITH MIGRAINE OR MIGRAINE-LIKE VASCULAR HEADACHES, REFRACTORY TO ESTABLISHED PREVENTIVE OR ABORTIVE THERAPIES, HAVE BEEN TREATED WITH DAILY ORAL GLUCOSAMINE. AFTER A LAG OF 4-6 WKS, A SUBSTATIAL REDUCTION IN HEADACHE FREQUENCY AND/OR INTENSITY HAS BEEN NOTED;IN SOME CASES, THE BENEFIT APPEARS TO BE DOSE-DEPENDENT. SINCE GLUCOSAMINE CAN BE A RATE-LIMITING PRECURSOR FOR MUCOPOLYSACCHARIDE SYNTHESIS, IT IS GERMANE TO NOTE PREVIOUS REPORTS THAT HEPARIN AND PENTOSAN POLYSULFATE MAY HAVE MIGRAINE-PREVENTIVE ACTIVITY. THERE IS REASON TO SUSPECT THAT MAST CELLS ARE CENTRAL MEDIATORS OF THE NEUROGENIC INFLAMMATION ASSOCIATED WITH MIGRAINE AND CLUSTER HEADACHES. THE HEPARIN PRODUCED BY MAST CELLS MAY FUNCTION TO PROVIDE FEEDBACK DOWN-REGULATION OF MAST CELL ACTIVATION, AND EXERTS A RANGE OF OTHER ANTI-INFLAMMATORY EFFECTS. WE POSTULATE THAT SUPPLEMENTAL GLUCOSAMINE CAN BOOST MAST CELL HEPARIN SYSTHESIS-PERHAPS CORRECTING A FUNCTIONAL HEPARIN DEFICIENCY-THEREBY PREVENTING OR AMELIORATING THE NEUROGENIC INFLAMMATION THAT MEDIATES PAIN IN VASCULAR HEADACHE. WHETHER OR NOT THIS IDEA HAS VALIDITY, A CONTROLLED STUDY OF GLUCOSAMINE FOR MIGRAINE PROPHYLAXIS APPEARS TO BE WARRANTED. |
| Dose amount | 1.5 GM |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |